0.509
price down icon1.17%   -0.006
 
loading
Exicure Inc stock is currently priced at $0.509, with a 24-hour trading volume of 18,687. It has seen a -1.17% decreased in the last 24 hours and a -19.03% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.5234 pivot point. If it approaches the $0.4986 support level, significant changes may occur.
Previous Close:
$0.515
Open:
$0.522
24h Volume:
18,687
Market Cap:
$4.40M
Revenue:
$28.83M
Net Income/Loss:
$3.07M
P/E Ratio:
0.303
EPS:
1.68
Net Cash Flow:
$-21.95M
1W Performance:
-12.06%
1M Performance:
-19.03%
6M Performance:
-19.21%
1Y Performance:
-44.39%
1D Range:
Value
$0.505
$0.522
52W Range:
Value
$0.3647
$1.50

Exicure Inc Stock (XCUR) Company Profile

Name
Name
Exicure Inc
Name
Phone
847 673 1700
Name
Address
2430 North Halsted Street, Chicago, IL
Name
Employee
37
Name
Twitter
@exicure
Name
Next Earnings Date
2024-04-24
Name
Latest SEC Filings
Name
XCUR's Discussions on Twitter

Exicure Inc Stock (XCUR) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-13-21 Downgrade Chardan Capital Markets Buy → Neutral
Dec-18-20 Initiated BMO Capital Markets Outperform
Nov-20-19 Initiated Guggenheim Buy

Exicure Inc Stock (XCUR) Financials Data

Exicure Inc (XCUR) Revenue 2024

XCUR reported a revenue (TTM) of $28.83 million for the quarter ending December 31, 2022, a +6,068% rise year-over-year.
loading

Exicure Inc (XCUR) Net Income 2024

XCUR net income (TTM) was $3.06 million for the quarter ending June 30, 2023, a +105.76% increase year-over-year.
loading

Exicure Inc (XCUR) Cash Flow 2024

XCUR recorded a free cash flow (TTM) of -$21.95 million for the quarter ending June 30, 2023, a +29.60% increase year-over-year.
loading

Exicure Inc (XCUR) Earnings per Share 2024

XCUR earnings per share (TTM) was $1.68 for the quarter ending June 30, 2023, a +110.31% growth year-over-year.
loading
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
$148.56
price up icon 3.08%
$82.17
price down icon 9.90%
$27.46
price down icon 3.55%
$143.71
price down icon 0.06%
$86.71
price down icon 1.57%
$368.60
price down icon 1.71%
Cap:     |  Volume (24h):